887
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Morphology and clinical characteristics of a case of FIP1L1-RARA fusion-associated variant acute promyelocytic leukemia

, &
Pages 499-502 | Received 19 Aug 2022, Accepted 20 Oct 2022, Published online: 09 Nov 2022

References

  • Scaglioni PP, Pandolfi PP. The theory of APL revisited. Curr Top Microbiol Immunol. 2007;313:85–100.
  • de Thé H, Chomienne C, Lanotte M, et al. The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature. 1990;347(6293):558–561.
  • Zelent A, Guidez F, Melnick A, et al. Translocations of the RAR alpha gene in acute promyelocytic leukemia. Oncogene. 2001;20(49):7186–7203.
  • Redner RL, Contis LC, Craig F, et al. A novel t(3;17)(p25;q21) variant translocation of acute promyelocytic leukemia with rearrangement of the RARA locus. Leukemia. 2006;20(2):376–379.
  • Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348(13):1201–1214.
  • Gotlib J, Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia. 2008;22(11):1999–2010.
  • Buijs A, Bruin M. Fusion of FIP1L1 and RARA as a result of a novel t(4;17)(q12;q21) in a case of juvenile myelomonocytic leukemia. Leukemia. 2007;21(5):1104–1108.
  • Kondo T, Mori A, Darmanin S, et al. The seventh pathogenic fusion gene FIP1L1-RARA was isolated from a t(4;17)-positive acute promyelocytic leukemia. Haematologica. 2008;93(9):1414–1416.
  • Menezes J, Acquadro F, Perez-Pons de la Villa C, et al. FIP1L1/RARA with breakpoint at FIP1L1 intron 13: a variant translocation in acute promyelocytic leukemia. Haematologica. 2011;96(10):1565–1566.
  • Wang Y, Rui Y, Shen Y, et al. Myeloid sarcoma type of acute promyelocytic leukemia with a cryptic insertion of RARA into FIP1L1: the clinical utility of NGS and bioinformatic analyses. Front Oncol. 2021;11:688203.
  • Nakanishi T, Nakaya A, Nishio Y, et al. A variant of acute promyelocytic leukemia with t(4;17)(q12;q21) showed two different clinical symptoms. Hematol Rep. 2019;11(3):7971.
  • Iwasaki J, Kondo T, Darmanin S, et al. FIP1L1 presence in FIP1L1-RARA or FIP1L1-PDGFRA differentially contributes to the pathogenesis of distinct types of leukemia. Ann Hematol. 2014;93(9):1473–1481.
  • Testa U, Lo-Coco F. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients. Ann Hematol. 2016;95(5):673–680.
  • Cicconi L, Divona M, Ciardi C, et al. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukemia treated with ATRA and ATO or ATRA and chemotherapy. Leukemia. 2016;30(10):1987–1992.
  • Breccia M, Avvisati G, Latagliata R, et al. Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. Leukemia. 2007;21(1):79–83.